PubMed Health⌕ Search

Biomedical subjects

F Tron

Publications and source records attributed to F Tron.

142 records · Page 8Linked to original sources
PubMed1980

[Circulating anticoagulants with antiprothrombinase activity in systemic lupus erythematosus (author's transl)].

Circulating anticoagulants with antiprothrombinase activity were detected in 14 out of 49 patients (i.e. 29%) presenting with severe forms of systemic lupus erythematosus (SLE) predominantly renal (29) or extrarenal (20). Nine of these 14 patients had thrombopenia and 8 had a falsely positive Wassermann test. The anticoagulants were more frequently encountered in patients with severe extrarenal manifestations (9/20 cases) than in patients with severe proliferative renal lesions (5/29 cases). They were found in 5 out of 10 patients with arterial and/or venous thrombosis. Anticoagulant levels paralleled the course of the disease during treatment. No haemorrhage was observed in 14 percutaneous renal biopsies performed on 11 patients free from outer coagulopathies. This suggests that the presence of antiprothrombinase anticoagulants in the blood of patients without thrombopenia or other coagulation disorders is compatible with surgery or biopsy of the kidney.

Blood Coagulation↗
PubMed1980

[Treatment of severe systemic lupus erythematosus. Long-term results in 55 patients (author's transl)].

Out of 55 patients with severe systemic lupus erythematosus (SLE) retrospectively studied from 1962 to 1979, 32 had diffuse proliderative glomerulonephritis and 23 had one or several extrarenal and/or haematological manifestations of the disease. All received corticosteroids in high dosage (0,8 to 1,5 up period was 48 months from the beginning of treatment. The actuarial survival rates for the whole groupe after 1,5 and 10 years were 92,4%, 83,4% and 77,2% respectively. Eight patients died: 5 of SLE and 3 of iatrogenic complications. Four are kept alive by maintenance haemodialysis. At the end of the study period, SLE was quiescent in 37 patients, including 14 who had discontinued corticosteroids for 5 to 72 months. The five-year survival rates were very similar in patients with renal and extrarenal involvement (86,4% and 81,6% respectively). In the latter group myocardial insufficiency, thrombopenia and thromboembolic complications were the main factors of morbidity and mortality. Corticosteroids were administered alone to 25 patients and in combination with cyclophosphamide to the remaining 30. Cyclophosphamide was given initially in 13 cases or subsequently on account of intolerance (7 cases) or resistance (10 cases) to steroids. Similar results were obtained with these two therapeutic regimens, but it must be noted that cyclophosphamide was mainly used in the more severe forms of SLE.

Adrenal Cortex Hormones↗
PubMed1980

Direct evaluation of class-specific anti-DNA antibodies by an immunoenzymatic technique.

Antibodies against native DNA have been evaluated by an immuno-enzymo assay (ELISA) using glucose oxidase labelled Ig class-specific antibodies. Results of the ELISA test were significantly correlated with those of the Farr test performed with native DNA as well as with the degree of clinical activity. ELISA is proposed as a simple method for the direct evaluation of class-specific anti-native DNA antibodies in systemic lupus and related diseases.

Antibodies, Antinuclear↗
PubMed1980

[Thromboembolic manifestations in systemic lupus erythematosus (author's transl)].

Among 60 patients (56 females, 4 males) with severe forms of SLE, 13 developed thromboembolic arterial and/or venous manifestations, an overall incidence of 21.6 percent. Thrombophlebitis episodes, mainly affecting lower limbs, occurred in 8 patients, usually an initial or early manifestation of active lupus disease; thrombophlebitis was recurrent in two, and pulmonary embolism was proved in two patients. Arterial occlusion developed in 7 patients, early in the course of active SLE and mainly affecting peripheral arteries in 4, later and affecting coronary arteries in three. In two patients, both arterial and venous manifestations occurred simultaneously or successively. A circulating anticoagulant with antiprothrombinase activity was present in 8 (61 percent) of the 13 patients with thromboembolic manifestations, as compared to only 21 percent of those without such manifestations, a highly significant (p less than 0.001) difference.

Arteries↗
PubMed1979

Immunologically-mediated acute renal failure of nonglomerular origin in the course of systemic lupus erythematosus [SLE]. Report of two cases.

Acute anuric renal failure was observed in two patients with systemic lupus erythematosus (SLE) during the clinical and serologic active phase of the disease. Renal biopsies, performed during the acute episodes, showed only mild and focal mesangial cell proliferation without deposits. In contrast, tubulointerstitial lesions were predominant. Intense granular immune deposits along the tubular basement membrane, or immunofluorescence examination, were suggestive of immune complex deposition. One of these patients had severe high blood pressure and vascular lesions likely induced by immune complexes. In both, renal function was recovered. Immunologically-mediated tubular and vascular lesions in the course of SLE are discussed.

Acute Kidney Injury↗
PubMed1978

[Controlled trial of levamisole in rheumatoid arthritis. Clinical and immunological study of 22 cases (author's transl)].

The results of a controlled trial in 22 patients indicated that levamisole, administered in a dose of 150 mg per day for 2 months, was more effective than a placebo on the clinical symptoms and signs of rheumatoid arthritis. Side effects were seen in 8 of the 12 patients treated with levamisole. They necessitated the premature interruption of treatment in three, but were never serious (no cases of agranulocytosis were seen). In the group treated with levamisole, there was a slight decrease in sedimentation rate, a significant fall in levels of the C3 fraction of serum complement and of circulating immune complexes (detected by polyethylene glycol), and a significant increase in cutaneous reaction to tuberculin and to candidin. By contrast, there were no significant variations in levels of rheumatoid factor, serum immunoglobulins, C4 fraction of complement, lymphocyte transformation indices in the presence of six dilutions of phytohaemagglutinin, nor in the percentages of T and B lymphocytes. The effectiveness of levamisole in rheumatoid arthritis would appear to be demonstrated, but its mode of action remains open to discussion, in the absence of any definite correlation between therapeutic activity and the immunostimulant effects of the drug.

Antigen-Antibody Complex↗
PubMed1977

[Immunological tests in the diagnosis and prognosis of disseminated lupus erythematosus, before treatment (author's transl)].

Sixty-four patients classified according to clinical manifestations, and renal pathological lesions have been submitted to a detailed immunological study before treatment. Four tests have provided significant correlations: antinative DNA antibodies (studied by a Farr test), C3, E rosette and cryoglobulins. The simultaneous considerations of these 4 parameters is however necessary in a given patient because each of them, taken separately, has no absolute value and may sometimes be clearly abnormal in patients with apparently benign outcome.

Adolescent↗
PubMed1977

Relationships between antibodies to native DNA and glomerulonephritis in systemic lupus erythematosus.

Anti-native DNA antibodies have been evaluated in forty-six lupus patients' sera for antigen-binding capacity, affinity and precipitating activity. Diffuse proliferative glomerulonephritis was significantly correlated with the presence of high serum level of free anti-native DNA antibodies. Weak affinities were more often found in patients with than without glomerular changes but several patients had high-affinity anti-DNA antibodies and severe glomerulonephritis. No correlation was found between anti-DNA antibody-precipitating activity and renal lesions.

Antibodies, Antinuclear↗